key: cord-0785433-rrvftrcp
authors: Klimstra, William B.; Tilston-Lunel, Natasha L.; Nambulli, Sham; Boslett, James; McMillen, Cynthia M.; Gilliland, Theron; Dunn, Matthew D.; Sun, Chengun; Wheeler, Sarah E.; Wells, Alan; Hartman, Amy L.; McElroy, Anita K.; Reed, Douglas S.; Rennick, Linda J.; Duprex, W. Paul
title: SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients
date: 2020-08-21
journal: J Gen Virol
DOI: 10.1099/jgv.0.001481
sha: 4ad058f917661d766a59655475788eaa03f7132c
doc_id: 785433
cord_uid: rrvftrcp

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged at the end of 2019 and by mid-June 2020 the virus had spread to at least 215 countries, caused more than 8 000 000 confirmed infections and over 450 000 deaths, and overwhelmed healthcare systems worldwide. Like severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 and caused a similar disease, SARS-CoV-2 is a betacoronavirus. Both viruses use human angiotensin-converting enzyme 2 (hACE2) as a receptor to enter cells. However, the SARS-CoV-2 spike (S) glycoprotein has a novel insertion that generates a putative furin cleavage signal and this has been postulated to expand the host range. Two low-passage (P) strains of SARS-CoV-2 (Wash1 : P4 and Munich : P1) were cultured twice in Vero E6 cells and characterized virologically. Sanger and MinION sequencing demonstrated significant deletions in the furin cleavage signal of Wash1 : P6 and minor variants in the Munich : P3 strain. Cleavage of the S glycoprotein in SARS-CoV-2-infected Vero E6 cell lysates was inefficient even when an intact furin cleavage signal was present. Indirect immunofluorescence demonstrated that the S glycoprotein reached the cell surface. Since the S protein is a major antigenic target for the development of neutralizing antibodies, we investigated the development of neutralizing antibody titres in serial serum samples obtained from COVID-19 human patients. These were comparable regardless of the presence of an intact or deleted furin cleavage signal. These studies illustrate the need to characterize virus stocks meticulously prior to performing either in vitro or in vivo pathogenesis studies.

December 2019 Chinese authorities notified the World Health Organization (WHO) of a pneumonia of unknown aetiology [1] . As of 18 June 2020, the disease, subsequently named coronavirus disease 2019 (COVID-19) by the WHO (https://www. who. int/ docs/ default-source/ coronaviruse/ situation-reports/ 20200211-sitrep-22-ncov. pdf), had spread to 215 countries with 8 385 440 confirmed cases and 450 686 confirmed deaths worldwide (https://www. who. int/ emergencies/ diseases/ novel-coronavirus-2019, accessed 19 June 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2] was identified as the causative agent in January 2020 [3] . SARS-CoV-2 is an enveloped, non-segmented, single-stranded, positive-sense RNA virus, and has been classified as a betacoronavirus alongside severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in OPEN ACCESS China in 2002 [4, 5] , and Middle East respiratory syndrome coronavirus (MERS-CoV), which emerged in the Arabian Peninsula in 2012 [6] . SARS-CoV and MERS-CoV are most likely bat viruses that infect humans via intermediate hosts [7] [8] [9] . Although the reservoir species remains unidentified, SARS-CoV-2 is also thought to be a zoonotic bat virus [10] .

The SARS-CoV-2 genome encodes structural proteins, including the nucleo-(N), membrane (M), envelope (E) and spike (S) proteins, non-structural proteins and accessory proteins [3] . The multifunctional coronavirus N protein primarily encapsidates the viral (v) RNA and plays a role in virus replication, transcription and assembly, as well as modulating the host cell environment [11] . The coronavirus E protein is an integral membrane protein that forms viroporins, complexes that are essential for virus assembly and release [12] . The transmembrane glycoprotein, coronavirus M protein, is located in the viral envelope and is required for egress [13] . The S protein of coronaviruses is a type I fusion protein that is involved in attachment to human angiotensinconverting enzyme 2 (hACE2) at the cell membrane [14] and subsequent virus-to-cell fusion, which in turn liberates the vRNA into the cytoplasm [15] . To accomplish this, most coronavirus S proteins undergo host cell-mediated cleavage to generate the S1 protein, which is responsible for receptor binding, and the S2 protein, which is responsible for virus-tocell fusion [16] . The S2 polypeptide is further processed at the S2′ site to expose the fusion peptide [17, 18] . Coronavirus S protein processing and entry strategies vary. For example, the S protein of the prototypic coronavirus mouse hepatitis virus, is cleaved during biosynthesis in the infected cell, whereas the S protein of SARS-CoV remains uncleaved until receptor binding and entry of progeny virus during subsequent infections [19] .

Several proteases process coronavirus S proteins, depending on where and when this takes place. Proprotein convertases, extracellular proteases, cell surface proteases or lysosomal proteases can process the protein, depending on whether spikes are cleaved during virus packaging (e.g. furin), after virus release (e.g. elastase), after virus attachment to the host cell (e.g. TMPRSS2), or during virus entry by endocytosis (e.g. cathepsin L), respectively [20] . Sequence analysis of SARS-CoV-2 S protein from human cases shows an insertion at the S1/S2 boundary versus closely related coronaviruses. This generates a novel, putative, furin cleavage signal not seen in other clade members [21] . It was subsequently shown that prior furin cleavage enhanced entry of a pseudovirus containing the SARS-CoV-2 S protein into different cell lines expressing hACE2 [22, 23] . The furin cleavage site is also required for SARS-CoV-2 infection of human lung cells [24] .

The S protein, along with the N and M proteins, is also a major antigenic target. A study of T cell responses to SARS-CoV-2 found that CD4 + cells were directed predominantly against S, N and M proteins and CD8 + cells were directed predominantly against S and M proteins, with significant reactivity also against N protein, along with some nonstructural proteins [25] . Using an N-protein enzyme-linked immunosorbent assay (ELISA), IgM and IgA antibodies have been detected as early as 3 days post-symptom onset (p.s.o.), with IgG antibodies detected as early as 10 days p.s.o [26] . The S protein is the major target for neutralizing antibodies [27, 28] and neutralizing antibody titres were reported to be higher in older COVID-19 patients [28] . However, this may reflect a correlation between age and disease severity rather than an effect of age alone [29] . Two linear B cell epitopes have been reported on the S protein and it was shown that antibodies recognizing these epitopes accounted for a high proportion of the anti-S neutralizing antibody response [30] .

In this study we aimed to characterize SARS-CoV-2 isolates from two sources virologically and immunologically and determine the impact passage in Vero E6 cells had on genetic stability. We identified perturbations of the S protein sequence at the S1/S2 boundary in the region of the furin cleavage signal, and subsequently investigated if there were differences in neutralizing antibody titres for viruses that have different sequences in this region. Neutralization activity was assessed using serial serum samples from acutely infected COVID-19 patients. Such analyses are critical for standardization of virus strains prior to generation of cDNA clones, examination of in vitro cell interaction characteristics, pathogenesis studies and identification of appropriate challenge strains for vaccine and therapeutic efficacy studies.

Virus growth and assays were performed at biosafety level 3 (BSL-3) conditions in the Regional Biocontainment Laboratory (RBL) in the Center for Vaccine Research at the University of Pittsburgh. All infectious material was inactivated using University of Pittsburgh Biohazards/Biosafety committee-approved protocols prior to removal from BSL-3 to allow assays to be conducted at lower containment.

Vero 76 cells, clone E6 (Vero E6), were purchased from ATCC and were grown in DMEM (Dulbecco's Modified Eagle Medium; Corning) supplemented with 10 % (v/v) foetal bovine serum (FBS; Atlanta Biologicals), 1 % (v/v) l-glutamine (Corning) and 1 % (v/v) penicillin/streptomycin (pen-strep; Corning).

Deidentified serum samples from three acutely infected COVID-19 (PCR-confirmed) patients treated at University of Pittsburgh Medical Center (UPMC) were received, aliquoted at BSL-2+ (Table 1) . These specimens were obtained as excess pathological specimens under an institutional review board (IRB)-approved protocol (STUDY20040220). 

Tenfold serial dilutions of virus stock were prepared in virus dilution medium and were added, in duplicate, to confluent Vero E6 monolayers in six-well plates (Corning; 200 µl/well). After 1 h of incubation at 37 °C, 5 % CO 2 , 2 ml/well of virus growth medium containing 0.1 % (w/v) immunodiffusion agarose (MP Biomedicals) was added and incubation was continued for 96 h. Plates were fixed with 2 ml/well formaldehyde [37 % (w/v) formaldehyde stabilized with 10-15 % (v/v) methanol; Fisher Scientific] for 15 min at room temperature. Agarose and fixative were discarded and 1 ml/well 1 % (w/v) crystal violet in 10 % (v/v) methanol (both Fisher Scientific) was added. Plates were incubated at room temperature for 20 min and then rinsed thoroughly with water. Plaques were then enumerated.

Four hundred microlitres of Tri-Reagent (Thermo Fisher) was added to 100 µl of virus stock and incubated for 10 min at room temperature. Five microlitres of polyacryl carrier (Molecular Research Center) was added to the specimen/ Tri-Reagent mixture, and incubated at room temperature for 30 s. Next, 200 µl of chloroform was added to the sample, which was inverted vigorously for 30 s before centrifugation at 12000 r.p.m. for 15 min at 4 °C. The aqueous phase was collected, mixed with an equal volume of 100 % isopropanol and incubated for 10 min at room temperature before centrifugation at 12000 r.p.m. for 10 min at 4 °C to pellet the RNA. The supernatant was removed and the RNA pellet was washed with 1 ml of 70 % (v/v) ethanol before centrifugation at 12000 r.p.m. for 5 min. The wash and centrifugation step was repeated, after which the supernatant was removed and the RNA pellet was allowed to air dry for 5 min before suspension in 40 µl of nuclease-free water. The RNA was stored at −80 °C until reverse transcription quantitative polymerase chain reaction (RT-qPCR) and sequence analyses.

For quantitation of vRNA, one-step RT-qPCR was performed using the 4× Reliance One-Step Multiplex RT-qPCR Supermix (BioRad), following the manufacturer's instructions. Primers and probe targeting the N gene sequence were as designed and optimized by the Centers for Disease Control and Prevention ( Table 2 ). The working concentrations for the forward and reverse primers and probe were 20 µM, 20 µM and 5 µM, respectively. Reverse transcription occurred at 50 °C for 10 min, followed by a polymerase activation step at 95 °C for 10 min, and a cycling PCR amplification (40 cycles) comprising 95 °C for 10 s and 60 °C for 30 s. Quantitation of vRNA was determined by comparing the cycle threshold (C T ) values from the unknown samples to C T values from a positive-sense SARS-CoV-2 vRNA standard curve generated from 1 : 10 serial dilutions of template, which was synthesized in-house by in vitro transcription using the mMessage mMachine T7 kit (Ambion) and following the manufacturer's instructions. The parent plasmid used for generation of the vRNA consists of a 944 bp region of the N gene cloned into pGEM52. The limit of detection was 23.2 RNA molecules. This RNA molecule quantification includes virus genome, antigenome and subgenomic RNA, but since the antigenome contribution was predicted to be small, the subgenomic RNA contribution was dependent on genome/ antigenome frequency and we were comparing changes in genome copies rather than absolute genome copy numbers, we used this measure as an indication of genome copies.

Reverse transcription/polymerase chain reaction (RT-PCR) was performed on virion RNA from virus stock passages using a range of primers ( The antibody was removed and the membranes were washed five times for 10 min with TBST buffer. The membranes were incubated with a working solution of enhanced chemiluminescence ECL Western blotting substrate (Pierce) for 5 min at room temperature. Excess substrate was removed and the membrane was exposed to X-ray film.

Human serum samples ( 

Two viruses isolated from clinical samples were obtained. CDC/2019n-CoV/USA_WA1/2020 (Wash1) was isolated from the first COVID-19 case in Washington, USA, and was received after four passages in Vero CCL-81 cells (P4) [31] . A second virus, SARS-CoV-2/München-1.1/2020/929 (Munich) was isolated from a hospitalized patient in Munich, Germany, and was received directly after the initial isolation in Vero E6 cells (P1) [32] . We further passaged both viruses twice in Vero E6 cells to obtain large-volume working stocks at P6 and P3, respectively, since these cells are known to support efficient production [31] . An agarose overlay plaque assay was developed and each virus stock was titrated by plaque assay on Vero E6 cells. Titres of 3.55×10 6 p.f.u. ml −1 and 3.25×10 5 p.f.u. ml −1 were obtained for Wash1 : P6 and Munich : P3, respectively. Passage resulted in an apparent increase in the overall plaque size for both viruses (Fig. 1a, b ). An immunoplaque assay was developed to ensure that the virus was SARS-CoV-2. SARS-CoV-2 antigens were detected using an anti-N polyclonal antibody (Fig. 1c) . Variation in plaque size was observed for both strains and the immunoplaque assay was useful in determining accurate viral titres, since it was discriminatory between infected and uninfected cells.

Virus passage in vitro, particularly in Vero cells, can alter the virus particle-to-p.f.u. ratio as well as plaque sizes, as the virus adapts to the cells used for culture [33, 34] . We examined the genome copies (as a proxy for particles)-to-p.f.u. ratio for each virus at each passage (Fig. 1d) . For the Wash1 virus the ratio decreased >10-fold from 2×10 6 to 4×10 4 between P4 and P6. However, for the Munich virus, the ratio dropped from 1.5×10 6 at P1 to 2×10 5 at P2 but then partially recovered to 5.5×10 5 on the next passage.

Amplicons from Wash1 : P4, P5 and P6 and Munich : P1, P2 and P3 stocks were examined by Sanger consensus sequencing across the S1 (red line)/S2 (black line) junction (Fig. 1a, b) .

Overlapping peaks were absent in the electrochromatograms for Munich : P1 and Wash1 :P4 but appeared in subsequent passages. The Wash1 : P4 virus stock originally received from Centers for Disease Control and Prevention (CDC) and a P5 virus stock had S protein sequences that exactly matched the published sequence in this region. Sequencing using forward and reverse primers demonstrated significant heterogeneity around the S1/S2 junction in the Wash1 : P6 passaged virus (Fig. 1a, right-hand panel) . Changes were undetectable in the Munich : P1 stock, but one position demonstrated heterogeneity as a minor peak on the chromatograms for a P2 stock and was enriched on the P3 electrochromatograms (Fig. 1b, (Fig. 2a) , which is commonly reported for cDNA libraries [35, 36] . Basic variant detection was used to identify possible single and multiple nucleotide changes and deletions in the sequences encoding the S1/S2 The first row contains the wild-type sequences and red and black text indicates the putative S1 and S2 subunits, respectively, generated after cleavage. Lower case nucleotide sequences indicate point mutations and -indicates nucleotide/amino acid deletions. Several different nucleotide variants gave rise to the same amino acid variant, denoted by (1) .

region of the S protein (Fig. 2b) . Twenty-two representative single-molecule reads obtained from the MinION sequencing of the Wash1 : P6 stock over a 100 nucleotide region were selected, aligned (Fig. 2c) , and then translated and aligned (Fig. 2d) to published nucleotide and protein sequences, respectively. All single-molecule reads covering the same region were analysed and the frequency of each individual variant in the swarm was calculated (Fig. 2e) . The minority (21%) of the sequences in the MinION swarm retained the six amino acid consensus sequence (RRARSV). The majority (79 %) had single and/or multiple nucleotide changes and/or deletions that removed the entire furin cleavage signal, with one such amino acid variant, PRQSIIAY, accounting for 23 % of the total single-molecule reads (Fig. 2e) . These changes would be predicted to render the resulting S proteins furinuncleavable and the consequences for studies of COVID-19 pathogenesis in animal models of disease may be significant. The Wash1 : P6 stock also contained one other high-frequency nucleotide change, resulting in an amino acid change (T323A) that was present with a frequency of 25 % (Table 3) . We did not observe any deletions in the MinION sequencing for the Munich : P3 stock, although there were four high-frequency (greater than 25 %) nucleotide changes resulting in amino acid changes (L368P, D614G, S686G and T941P; Table 3 ).

Since multiple deletions of the furin cleavage signal were present in the Wash1 : P6 virus stock, we analysed cleavage of the S protein biochemically by developing an immunoblot to examine whole-cell lysates prepared from virusinfected Vero E6 cell monolayers (Fig. 3a) . As expected the S protein from Wash1 : P6 stock containing the deletions was uncleaved. However, the S protein was also uncleaved for a Wash1 : P5 stock, in which the cleavage signal was intact (Fig. 1a) . Similarly, the protein was not cleaved for either P2 or P3 Munich, for which the cleavage signal was intact (Fig. 1b) . In contrast, an S protein expressed from a codon-optimized gene cloned into pCAGGS was cleaved efficiently (Fig. 3a, lane 2 ). An immunoblot performed using an antibody to the SARS-CoV-2 N protein on the same Vero E6 cell lysates showed similar expression levels for each virus infection (Fig. 3b) .

We established an indirect immunofluorescence assay to determine the expression and localization of SARS-CoV-2 N and S proteins in infected cells. Based on our virological and sequence analyses showing that the furin cleavage site was intact, Vero E6 cells were infected with Munich : P3 at an m.o.i. of 0.1 (for N assays) or 0.01 (for S assays) for 24 h. The N protein was present in a predominantly diffuse cytoplasmic distribution with some small areas of perinuclear accumulation (Fig. 3c) . This is consistent with previous observations [37] . We also studied S protein trafficking to the cell surface using Vero E6 cell monolayers that were infected as above and were either fixed and permeabilized or left non-permeabilized. In non-permeabilized cells, the S protein was present at significant levels in puncta, which were distributed across the cell membranes of infected cells (Fig. 3d, arrow) . This is consistent with the assembly and egress of SARS-CoV-2 through membranes between the endoplasmic reticulum and the Golgi intermediate compartment.

A close association of S protein with the actin cytoskeleton was seen when phalloidin was used to stain filamentous (f)-actin (Fig. 3d, e) . In this and other assays (not shown) cytopathic effect involved cell rounding and detachment from the dish and a degree of cell-tocell fusion was observed. Cells were permeabilized and equivalent indirect immunofluorescence was performed to examine the intracellular location of the SARS-CoV-2 S protein. A punctate distribution throughout the infected cell cytoplasm and the cell surface was observed (Fig. 3e) . The same infection conditions and indirect immunofluorescence assays were used to examine antibody reactivity in human serum obtained from acutely infected human COVID-19 patients (Fig. 3f) . In addition to perinuclear puncta, consistent with S protein localization, the antisera recognized SARS-CoV-2 proteins distributed diffusely throughout the cytoplasm. Cell rounding and increased staining were observed, consistent with cells in the later stages of the infection.

Given the readily detectable anti-SARS-CoV-2 antibody reactivity in the human serum (Fig. 3f) , we obtained a series of sera from three acutely infected COVID-19 patients to determine if these neutralized the virus (Table 1 ). Sera were collected from patients at multiple days p.s.o. and a PRNT 80 assay was developed using the Munich : P3 stock. This SARS-CoV-2 virus neutralization assay was performed in triplicate for all samples to examine the kinetics of antibody development in hospitalized patients at varying stages of the infection (Fig. 3g) . For all patients the first serum sample (ranging from 5 to 9 days after first reported symptoms) failed to neutralize SARS-CoV-2. However, seroconversion occurred in all patients the subsequent day and all samples neutralized. Assays were routinely validated using a non-specific human serum collected before circulation of SARS-CoV-2 in Pittsburgh (data not shown). For patient 1, neutralizing activity was first detected at 6 days p.s.o. and increased steadily until 16 days p.s.o. Likewise, the neutralizing activity of samples obtained from patient 2 increased with similar kinetics following the first detectable signal 8 days p.s.o. Although neutralizing activity was first detected at 10 days p.s.o. in patient 3, there was a remarkable difference in the rate of development and the strength of the neutralizing response compared to patients 1 and 2. This patient had the highest titre of the three, reaching a stable PRNT 80 of 1600 both at 13 and 14 days p.s.o. This was at the higher end of titres published by other groups using equivalently timed sera and comparable assay conditions [38] [39] [40] [41] [42] . Interestingly, for the earlier days p.s.o. where samples were available for either two or all three of the patients, the titres were quite similar. Since the Wash1 : P6 virus stock had deletions in the furin cleavage signal, we investigated whether using this virus would confound a PRNT 80 assay using serum (day 14) from patient 3. Both viruses were equivalently neutralized by this serum reaching the same PRNT 80 of 1600. It is possible that this result was influenced by the cell line used for stock preparation, as both viruses exhibited similar S cleavage when grown on Vero E6 cells (Fig. 3a) .

Virus provenance is critical in studies that aim to understand pathogenesis and test interventions such as antivirals, antibodies and vaccines. The emergence of SARS-CoV-2 and the rapid proliferation of studies must therefore be augmented by solid virological assays and a comprehensive understanding of the pathogen genetically and immunologically. Here we systematically characterized European and North American isolates of SARS-CoV-2 passaged in Vero E6 cells, as the majority of researchers use them worldwide.

Since we are studying SARS-CoV-2 pathogenesis in a wide range of animal species (including non-human primates [43] A study using retroviral pseudoviruses incorporating the SARS-CoV-2 S protein into virions [47] demonstrated that a mutant S protein in which the S1/S2 cleavage site region Q 677 TNSPRRAR/SV 687 was changed to Q 677 TILR/SV 683 , removing the furin cleavage signal, facilitated enhanced entry of the pseudovirus into Vero E6 cells. A further study using rhabdoviral pseudoviruses [24] concluded that TMPRSS2 activity is required for SARS-CoV-2 entry into the human lung cell line Calu-3 and a second study from the same group [48] proposed that furin-mediated cleavage at the S1/S2 site promotes subsequent TMPRSS2dependent entry into target cells. Vero cells are TMPRSS2deficient [49] , and SARS-CoV-2 entry into them is likely cathepsin-mediated [50] . Taken together, these studies suggest that there may be no advantage to retention of the furin cleavage signal in Vero cells and that presence of the sequence may actually be detrimental to entry of the virus into these cells. This explains why the deleted virus quickly became predominant in our studies. We did not detect a similar perturbation of the furin cleavage signal in the Munich stock, although this virus has had fewer total passages in Vero E6 cells, and we postulate that once a similar change occurs it will be rapidly selected for with continued passage in Vero E6 cells. The Munich strain of SARS-CoV-2, which was passaged three times less in Vero E6 cells, had a more consistent genome copies-to-p.f.u. ratio and a stable overall titre, as determined by plaque assay. From these data, we conclude that an increase of ~1 log in SARS-CoV-2 titres should be considered to be indicative of cell adaptation.

Four high-frequency (>25 %), single, non-synonymous nucleotide changes versus the SARS-CoV-2 Wash1 genome sequence were detected in the Munich S gene (Table 3) . D614G [51, 52] was present in all passages sequenced and has been suggested to increase the transmission efficiency of the virus [53] . It has also recently been reported that the mutation allowed retrovirus pseudotypes to enter hACE2expressing cells with greater efficiency [54] . S686G was first detected in P2 sequencing and was enriched upon passage in Vero E6 cells. This change is located at the putative S1/ S2 cleavage site with the amino acid, presumably, constituting the new amino-terminus of S2 upon cleavage. This serine residue, along with S673 and T678, has also been predicted to be subject to O-linked glycosylation, due to the inserted (relative to other members of the betacoronaviruses) proline at position 681 just upstream [55] . It has been shown for Sindbis virus that when a mutation, introducing an N-linked glycosylation site, is placed adjacent to the furin cleavage site of the PE2 glycoprotein, cleavage is blocked [56] . Whether the S686G change in Munich : P3 has any impact on cleavage efficiency and whether this site is in fact glycosylated, and the biological consequences thereof, remain to be determined experimentally. T941P is also a potentially significant mutation, since it is located in the fusion core of heptad repeat 1, and modelling of changes in this region have recently been shown to lead to the loss of interactions stabilizing the post-fusion assembly [57] .

An important observation was that S proteins containing intact furin cleavage signals remained uncleaved in infected Vero E6 cell lysates. Although some studies report Western blot analysis showing cleavage of the S protein [22, 24, 47, 48, 58] , they examine S protein from purified pseudovirus and not SARS-CoV-2-infected Vero E6 cell lysates. One study using human serum to detect proteins in infected Vero E6 cell lysates [39] showed mainly uncleaved S protein with a trace of bands for S1 and S2 visible at the lowest serum dilution tested. Although it is possible that the antibodies in the human serum predominantly recognize uncleaved S protein, it is likely that in this study the S protein was also not cleaved efficiently in the Vero E6 cells.

Our data suggest that, specifically in Vero E6 cells, the S protein is not cleaved efficiently during protein biosynthesis in the infected cell, but rather at a later stage, i.e. during packaging and release or upon attachment or entry to the next host cell. Follow-up studies examining the cleavage state of the SARS-CoV-2 S protein on purified virions would be informative in this respect. Interestingly, the fact that the pCAGGS-expressed protein was cleaved efficiently in the cells suggests either that the codon optimization of the S gene affects an aspect of protein expression or that the fully replicating SARS-CoV-2 suppresses cleavage in infected Vero E6 cells. This is potentially important for vaccine developers who are using codon optimization.

Genome copies-to-p.f.u. ratios decreased for the Wash1 virus upon passage from P4-P6. Although we did not examine them, it is likely that this represents a reduction in virus particles. This potential reduction in virus particles may have implications for SARS-CoV-2 pathogenesis studies, since it has been well documented with alphaviruses, also enveloped positive-sense RNA viruses, that decreases in particle-to-p.f.u. ratios observed with passage correlate with enhanced infection efficiency for cells on which the viruses were amplified. With alphaviruses, this often involves the accumulation of neutral or negatively charged to positively charged amino acid substitution mutations that enhance binding to cell surface heparan sulfate [34, [59] [60] [61] . Furthermore, passaged viruses are generally attenuated in animal models of disease either through the effects of efficient heparan sulfate binding on virus dissemination or reduction in actual particle doses given when plaque-forming units were used to determine inocula [59, 60, 62, 63] . However, we did not observe mutation to positively charged amino acids in the SARS-CoV-2 S protein with passage, suggesting that a different selective pressure might be in play.

The neutralization assays were developed using Munich : P3 stock, since it had no deletions in the furin cleavage signal.

Since the neutralizing antibody titres we determined are at the high end of those reported by other groups [38] [39] [40] [41] [42] , we investigated whether there was any difference in neutralizing capacity against the Wash1 : P6 mixed population virus stock, with a deletion in the cleavage signal. There was no difference in neutralization capacity between the two virus stocks. This suggests that the use of a virus containing the furin cleavage site deletion in such assays should not affect the detection of neutralizing antibodies, or the titres thereof, at least when virus stocks are prepared on Vero E6 cells. Follow-up studies, which lie beyond the scope of the present communication, using other disease-relevant cell types and cells over-expressing proteases such as furin, which may cleave the SARS-CoV-2 S proteins, will be critical to undertake, as will the assessment of the relative levels of cleaved versus uncleaved S protein in infectious virus particles. These data demonstrating perturbation of the furin cleavage signal during cell culture led us to halt using Vero E6-derived Wash1 stocks for pathogenesis studies in animals. An important conclusion from this work is that SARS-CoV-2 used to infect animals should be the lowest passage level possible and confirmed by sequencing. This will be especially relevant for efficacy studies of vaccines and antivirals.

Funding for this study was provided by Dr Patrick Gallagher, Chancellor of the University of Pittsburgh, and by the Center for Vaccine Research. The project described was also supported by the University of Pittsburgh Clinical and Translational Science Institute (NIH TR001857) and the DSF Charitable Foundation. C. M. M was funded through NIH T32 AI060525.

2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak -United States

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A novel coronavirus from patients with Pneumonia in China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus associated with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Close relative of human middle East respiratory syndrome coronavirus in bat

Viruses in bats and potential spillover to animals and humans

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The coronavirus nucleocapsid is a multifunctional protein

The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles

Membrane binding proteins of coronaviruses

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Ready, set, fuse! the coronavirus spike protein and acquisition of fusion competence

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner

Host cell proteases: critical determinants of coronavirus tropism and pathogenesis

Structure, function, and evolution of coronavirus spike proteins

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Cell entry mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)

Cross-Reactive antibody response between SARS-CoV-2 and SARS-CoV infections

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

High neutralizing antibody titer in intensive care unit patients with COVID-19

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States

Virological assessment of hospitalized patients with COVID-2019

Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques

Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor

Opportunities and challenges in long-read sequencing data analysis

A comprehensive examination of nanopore native RNA sequencing for characterization of complex transcriptomes

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland

Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts

Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site

Identification of common deletions in the spike protein of SARS-CoV-2

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity

Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

The proximal origin of SARS-CoV-2

Lethality of PE2 incorporation into Sindbis virus can be suppressed by second-site mutations in E3 and E2

D936Y and other mutations in the fusion core of the SARS-Cov-2 spike protein heptad repeat 1 undermine the Post-Fusion assembly

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. eCell Host and Microb

Heparan sulfate binding can contribute to the neurovirulence of neuroadapted and nonneuroadapted Sindbis viruses

Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice

Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipidconjugated heparin

Infection of neonatal mice with Sindbis virus results in a systemic inflammatory response syndrome

Deliberate attenuation of Chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design

We thank Dr Natalie Thornburg (CDC Atlanta) and Drs Christen Drosten and Jan Felix Drexler (Charité -Universitätsmedizin Berlin) for providing SARS-CoV-2 isolates (CDC/2019n-CoV/USA_WA1/2020 from the USA and Munchen-1.1/2020/929 from Germany). We appreciate the efforts of the University of Pittsburgh Department of Environmental Health and Safety for timely regulatory and logistical oversight of this work under pandemic conditions. We are grateful to Andrew Davidson and David Matthews for useful discussion regarding interpretation of MinION data. The help and encouragement of Kevin Washo, Chancellor's Office, University of Pittsburgh, who actively supported these studies from the outside is gratefully acknowledged. 

The authors declare that there are no conflicts of interest.

Five reasons to publish your next article with a Microbiology Society journal 1 . The Microbiology Society is a not-for-profit organization. 2. We offer fast and rigorous peer review -average time to first decision is 4-6 weeks. 3. Our journals have a global readership with subscriptions held in research institutions around the world. 4. 80% of our authors rate our submission process as 'excellent' or 'very good'. 5. Your article will be published on an interactive journal platform with advanced metrics.Find out more and submit your article at microbiologyresearch.org.